Research Use Only. Peptides Lab UK supplies research-grade materials for in-vitro laboratory research only. Nothing on this page is medical advice or an instruction for human or animal use, and no product sold on this website is a medicine.
What is SLU-PP-332?
SLU-PP-332 is a synthetic small-molecule agonist of the oestrogen-related receptors (ERRα, β and γ). It is not a peptide and has no marketing authorisation; it is a preclinical research tool.
Published research
In mouse studies SLU-PP-332 induced an ERRα-dependent acute aerobic exercise-type gene programme and increased exercise capacity, and in obese mouse models it was reported to improve features of metabolic syndrome. Further studies examined ERR agonism in heart-failure and ageing-kidney models. Analytical and in-vitro metabolism studies have been published for doping-control purposes.[1,2,3,4]
Limitations of the evidence
Much of the available literature is preclinical (cell and animal models) or comes from small numbers of research groups. Findings in defined experimental systems cannot be extrapolated to other settings, and this page does not provide dosing, administration or human-use information.
Laboratory handling and storage
Lyophilised peptides are generally stored sealed, protected from light and moisture, at low temperature as specified on the certificate of analysis. Once reconstituted for in-vitro work, solutions are typically kept refrigerated and used within a validated stability window. Researchers should follow their institution’s procedures and the batch documentation (HPLC purity and mass-spectrometry identity) supplied with each lot.
UK regulatory status
In the UK, medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). Research-grade compounds sold by Peptides Lab UK are supplied strictly for laboratory research; they are not medicinal products, are not manufactured to medicinal GMP standards and must not be used in humans or animals.
Related research pages
References
- Billon C et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol. 2023; 18(4):756-771. doi:10.1021/acschembio.2c00720 PMID: 36988910.
- Billon C et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024; 388(2):232-240. doi:10.1124/jpet.123.001733 PMID: 37739806.
- Xu W et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024; 149(3):227-250. doi:10.1161/CIRCULATIONAHA.123.066542 PMID: 37961903.
- Möller T et al. In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential. Rapid Commun Mass Spectrom. 2026; 40(8):e70039. doi:10.1002/rcm.70039 PMID: 41588687.
Disclaimer: All products sold by Peptides Lab UK are for laboratory research use only. Not for human or veterinary use, not for consumption, and not intended to diagnose, treat, cure or prevent any disease. This page is an educational literature summary and is not medical advice.
